Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF OCTOBER 28, 2021 SAM #7271
SOLICITATION NOTICE

65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Notice Date

10/26/2021 12:04:24 PM
 

Notice Type

Solicitation
 

NAICS

325412 — Pharmaceutical Preparation Manufacturing
 

Contracting Office

DEFENSE HEALTH AGENCY AURORA CO 80011 USA
 

ZIP Code

80011
 

Solicitation Number

HT9402-22-Q-0001
 

Response Due

12/15/2021 10:00:00 AM
 

Archive Date

06/15/2022
 

Point of Contact

Madison Northen, Hudson Tompkins
 

E-Mail Address

madison.r.northen.civ@mail.mil, hudson.w.tompkins.civ@mail.mil
(madison.r.northen.civ@mail.mil, hudson.w.tompkins.civ@mail.mil)
 

Description

Background: The Department of Defense (DoD) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: February 2022: The following drug classes/subclass will be reviewed: a.�Binders?Chelators?Antidotes?Overdose Agents - Subclass: Hypoglycemia Agents b.�Oncological Agents - Sub Class: Multiple: Epidermal Growth Factor Receptor (EGFR) + Non-Small Cell Lung Cancer (NSCLC); Myelofibrosis;� Non-Bruton's Tyrosine Kinase Inhibitor (Non-BTKI) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Renal Cell Carcinoma;� Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors;� Renal Cell Carcinoma The RFQ, including UF BPA and UF ADP appendices are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-22-Q-0001. Pre-proposal teleconference is on November 10, 2021, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/a4f9456dd43942348145f9e28c128c47/view)
 

Place of Performance

Address: San Antonio, TX 78230, USA

Zip Code: 78230

Country: USA
 

Record

SN06164840-F 20211028/211026230119 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |